New drug candidate GL-0719 enters first human safety trials for rare blood disorder
NCT ID NCT05318534
First seen Mar 09, 2026 · Last updated May 01, 2026 · Updated 7 times
Summary
This early-stage study tests a new drug called GL-0719 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy adults and in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures. The study involves a single injection (either into a vein or under the skin) and will monitor side effects and early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIRST IN MAN STUDY TO EVALUATE INITIAL SAFETY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fortrea Clinical Research Unit Ltd
RECRUITINGLeeds, LS2 9LH, United Kingdom
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.